ClinicalTrials.gg
TerminatedNCT05077969Updated Jul 9, 2024Results posted

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

A Phase 2 interventional study of Famotidine and Celecoxib in 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection and 2019-nCoV Disease, sponsored by Leidos Life Sciences. Terminated at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-09.

Sponsored by Leidos Life Sciences · Phase 2, Interventional, and Treatment

Why this study was terminated
Low recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing famotidine in COVID-19 — none open to participants now, 1 under way, none of them phase 3. Famotidine · COVID-19.

Enrollment
6th of 10
4 · median 5
Started
2021
with 4 others
Phase 2
6 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
3 of 10
Leidos Life Sciences

Among the 10 studies testing famotidine in COVID-19, this one is the 6th largest by enrollment, is one of 5 that started in 2021, is one of 6 in phase 2, and was the 7th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 10 studies testing famotidine in COVID-19 is open now. The open studies under COVID-19, anywhere →

Where they have run

About famotidine

Famotidine: first FDA approval 1986 (PEPCID). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing famotidine in COVID-19 as a file.
02

Study summary

This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib. Each of these agents separately demonstrate clinical activity in mitigating COVID-19 disease symptoms or severity, and each of which appear to have separate and complementary mechanisms of action.

Read the detailed description

Qualifying patients will have been confirmed positive for COVID-19 and have symptoms of World Health Organization (WHO) Ordinal Scale for Clinical Improvement with scores of ≤3 on the 11-point scale and will be randomly assigned, in a 1:1 ratio, to one of two regimens, with 659 participants per group, as follows:

Group 1 (study product) participants will receive 80 mg famotidine by mouth (PO) 4 times per day (QID) + 400 mg celecoxib as a first dose, followed by 200 mg celecoxib (PO) 2 times per day (BID), for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.

Group 2 (reference therapy) participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, participants will continue to receive matching famotidine placebo, QID, for an additional 9 days.

Safety and efficacy of famotidine and celecoxib will be evaluated.

This is a completely virtual trial and you can participate from your own home. Please call 1-888-370-9330 to speak to someone regarding study participation in your area.

03

Conditions studied

  • 2019 Novel Coronavirus Disease
  • 2019 Novel Coronavirus Infection
  • 2019-nCoV Disease
  • 2019-nCoV Infection
  • COVID-19
  • COVID-19 Pandemic
  • COVID-19 Virus Disease
  • COVID-19 Virus Infection
  • Covid19
  • Coronavirus Disease 2019
  • SARS-CoV2 Infection
  • SARS-CoV-2 Acute Respiratory Disease

Browse trials for

Keywords

  • COVID-19
  • COVID
  • COVID19
  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants must be at least 18 years of age, inclusive, at the time of signing the form.
  • Confirmed SARS-CoV-2 polymerase chain reaction (PCR) positive patient within 5 days of enrollment, as shown by medical history and reported PCR test result.
  • Reports having one or more symptoms consistent with SARS-CoV-2, as defined in Master Protocol Appendix 3 Table 4.
  • COVID-19 diagnosis must be WHO grade ≤3.
  • use by men or women should be consistent with Appendix 4 of the Master protocol (LDOS-21-001).
  • Reliable access to the Internet via a browser installed on personal device or computer.
  • Capable of understanding and providing signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Ongoing antiviral or antiretroviral treatment
  • Known history of
  • Ongoing anti-inflammatory treatment that cannot be temporarily discontinued during the study. This includes nonsteroidal anti-inflammatory drugs (NSAIDs), and - including Dexamethasone (dexamethasone administration restricted to recommended standard of care use per NIH COVID-19 Guidelines)

    1. drugs dependent on gastric pH for absorption, e.g., dasatinib, delavirdine, mesylate, cefditoren, and fosamprenavir;
    2. tizanidine (CYP1A2) substrate;
    3. drugs that interfere with hemostasis (e.g., warfarin, aspirin, selective serotonin reuptake inhibitors [SSRIs]/serotonin norepinephrine reuptake inhibitors (SNRIs]);
    4. angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), or beta-blockers;
    5. diuretics;
    6. digoxin
  • Ongoing treatment that cannot be temporarily discontinued during the study, with: antimalarials, antiarrhythmics, tricyclic antidepressants, natalizumab, quinolones, macrolides, agalsidase alfa and beta
  • Ongoing famotidine or celecoxib or other COVID-19 clinical treatment(s) within the past 30 days, or current participation in another investigational clinical trial
  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
  • History of
  • Rejection of participation by Principal Investigator or Sponsor
  • Any for famotidine or celecoxib treatment:

    1. Famotidine or celecoxib
    2. Retinopathy, visual field or visual acuity disturbances
    3. History of cardiovascular disease, such as congestive heart failure, , myocardial infarction, bradycardia (\<50 bpm), ventricular tachycardia, other arrhythmias
    4. Myasthenia gravis
    5. Psoriasis or porphyria
    6. History of renal failure/dialysis or a glomerular clearance \<60 mL/min
    7. History of severe hypoglycemia
    8. Moderate or severe hepatic impairment, e.g., Class B or C
    9. Known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history or experience with other CYP2C9 substrates, such as warfarin and phenytoin
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Group 1 (Study Product)

    Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.

    Drug: Famotidine · Drug: Celecoxib

  • Placebo comparator
    Group 2 (Reference Therapy)

    Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, participants will continue to receive matching famotidine placebo, QID, for an additional 9 days.

    Drug: Placebo

Interventions

  • 80 mg tablet, QID for 14 days

    Also known as: Pepcid

  • 400 mg (initial dose), then 200 mg capsule, BID for 5 days

    Also known as: Celebrex

  • DrugPlacebo

    tablet, QID for 14 days; capsule, BID for 5 days

06

What researchers measure

Primary outcomes

  1. Number of Patients With at Least One COVID-19-related Medically Attended Contact Due to Increased COVID-19 Symptom Severity

    Medically attended contact will be measured in whole numbers and reported as "1 medically attended contact" each time, in the electronic data capture system for all study participants.

    Time frame: Through Day 30

  2. Number of Patients With at Least One COVID-19-related Medically Attended Contact Due to Death (All-cause Mortality).

    Medically attended contact will be measured in whole numbers and reported as "1 medically attended contact" in the electronic data capture system for all study participants.

    Time frame: Through Day 30

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Serious Adverse Events (SAE) as Assessed by Participant Withdrawal

    Study discontinuation will be measured in whole units, by number of participants who are removed with the reason of "SAE" and captured by the electronic data capture system.

    Time frame: 90 days

  2. Incidence of Death

    Deaths will be captured by whole numbers, by number of participants who are removed from the study with reason as "death" in the electronic data capture system.

    Time frame: 90 days

07

Results

Posted Jul 9, 2024
Limitations and caveats
The study was not able to enroll the requisite number of patients to evaluate the prespecified endpoints. As a result the study was halted prematurely.

Participant flow

Participant flow — Overall Study
MilestoneGroup 1 (Study Product)Group 2 (Reference Therapy)
Started22
Completed12
Not completed10

Outcome measures

PrimaryNumber of Patients With at Least One COVID-19-related Medically Attended Contact Due to Increased COVID-19 Symptom Severity

Medically attended contact will be measured in whole numbers and reported as "1 medically attended contact" each time, in the electronic data capture system for all study participants.

Time frame:
Through Day 30
Reported as:
Count of participants · Participants
Number of Patients With at Least One COVID-19-related Medically Attended Contact Due to Increased COVID-19 Symptom Severity
ParticipantsGroup 1 (Study Product)Group 2 (Reference Therapy)
Number of Patients With at Least One COVID-19-related Medically Attended Contact Due to Increased COVID-19 Symptom Severity12
PrimaryNumber of Patients With at Least One COVID-19-related Medically Attended Contact Due to Death (All-cause Mortality).

Medically attended contact will be measured in whole numbers and reported as "1 medically attended contact" in the electronic data capture system for all study participants.

Time frame:
Through Day 30
Reported as:
Count of participants · Participants
Number of Patients With at Least One COVID-19-related Medically Attended Contact Due to Death (All-cause Mortality).
ParticipantsGroup 1 (Study Product)Group 2 (Reference Therapy)
Number of Patients With at Least One COVID-19-related Medically Attended Contact Due to Death (All-cause Mortality).00
SecondaryNumber of Participants With Treatment-Emergent Serious Adverse Events (SAE) as Assessed by Participant Withdrawal

Study discontinuation will be measured in whole units, by number of participants who are removed with the reason of "SAE" and captured by the electronic data capture system.

Time frame:
90 days
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Serious Adverse Events (SAE) as Assessed by Participant Withdrawal
participantsGroup 1 (Study Product)Group 2 (Reference Therapy)
Number of Participants With Treatment-Emergent Serious Adverse Events (SAE) as Assessed by Participant Withdrawal00
SecondaryIncidence of Death

Deaths will be captured by whole numbers, by number of participants who are removed from the study with reason as "death" in the electronic data capture system.

Time frame:
90 days
Reported as:
Count of participants · Participants
Incidence of Death
ParticipantsGroup 1 (Study Product)Group 2 (Reference Therapy)
Incidence of Death00

Adverse events

Collected over 90 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 (Study Product)0/2 (0%)0/2 (0%)1/2 (50%)
Group 2 (Reference Therapy)0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent other events
Most frequent other events
EventGroup 1 (Study Product)Group 2 (Reference Therapy)
Sinus HeadachesNervous system disorders1/20/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1 (Study Product)Group 2 (Reference Therapy)Total
<=18 years000
Between 18 and 65 years224
>=65 years000
Age, Continuous
Age, Continuous(years)Group 1 (Study Product)Group 2 (Reference Therapy)Total
Mean42.5 (40 to 45)27 (26 to 28)34.75 (26 to 45)
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 (Study Product)Group 2 (Reference Therapy)Total
Female224
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1 (Study Product)Group 2 (Reference Therapy)Total
Hispanic or Latino000
Not Hispanic or Latino224
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1 (Study Product)Group 2 (Reference Therapy)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White224
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Group 1 (Study Product)Group 2 (Reference Therapy)Total
United States224
08

Study locations

15 sites
  • Integrated Therapeutic Solutions USA, Inc.
    Newport Beach, California 92603, United States
  • Integrated Therapeutic Solutions USA, Inc.
    Miami, Florida 33126, United States
  • Integrated Health Solutions USA, Inc.
    Atlanta, Georgia 30363, United States
  • Integrated Therapeutic Solutions USA, Inc
    Hazlehurst, Georgia 31539, United States
  • Integrated Therapeutic Solutions USA, Inc.
    Chicago, Illinois 60611, United States
  • Integrated Therapeutic Solutions USA, Inc
    Prospect, Kentucky 40059, United States
  • Integrated Therapeutic Solutions USA, Inc
    Frederick, Maryland 21702, United States
  • Integrated Therapeutic Solutions USA, Inc
    Gaithersburg, Maryland 20878, United States
  • Integrated Therapeutic Solutions USA, Inc
    Rockville, Maryland 20850, United States
  • Integrated Therapeutic Solutions USA, Inc
    Dearborn, Michigan 48120, United States
  • Integrated Therapeutic Solutions USA, Inc.
    Newark, New Jersey 07102, United States
  • Integrated Therapeutic Solutions USA, Inc.
    New York, New York 10005, United States
  • Integrated Therapeutic Solutions USA, Inc.
    Huntingdon, Pennsylvania 16652, United States
  • Integrated Therapeutic Solutions USA, Inc.
    Charleston, South Carolina 29414, United States
  • Integrated Therapeutic Solutions USA, Inc.
    Dallas, Texas 75219, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — It is not yet known if there will be a plan to make individual participant data (IPD) available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jun 2022, 5 months.

Results were first posted in Jul 2024, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2021
First posted
Oct 14, 2021
StartActual
Dec 29, 2021
Primary completionActual
Jun 28, 2022
CompletionActual
Jul 8, 2022
Results first posted
Jul 9, 2024
Last update
Jul 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05077969
Lead sponsor
Leidos Life Sciences
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Oct 14, 2021
Start date
Dec 29, 2021
Primary completion
Jun 28, 2022
Completion
Jul 8, 2022
Results posted
Jul 9, 2024
Last update
Jul 9, 2024

Study contacts

Brian A Roberts, MS, PMP
study director · Leidos, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Famotidine · Celecoxib

Start the discussion